Objective:
To investigate the efficacy and safety of high-dose aflibercept (8 mg) compared to standard-dose aflibercept (2 mg) in patients with retinal vein occlusion (RVO), specifically including branch RVO (BRVO) and central RVO (CRVO).
Key Findings:
- The 8 mg aflibercept groups showed noninferiority to the 2 mg groups with a visual acuity gain of around 17 to 18 letters.
- Central retinal thickness (CRT) reductions were observed, averaging around 370 µm.
- Approximately 90% of patients in the 8 mg groups remained on Q8 week dosing, with nearly 70% assigned to longer treatment intervals by week 36.
Interpretation:
The study demonstrates that high-dose aflibercept is effective in improving visual acuity and reducing CRT in RVO patients, with a favorable safety profile, suggesting potential changes in clinical practice.
Limitations:
- The study is ongoing, with final results expected at week 64, which may affect the interpretation of the current findings.
- Differences in outcomes between branch RVO (BRVO) and central RVO (CRVO) have yet to be analyzed, which could impact the overall conclusions.
Conclusion:
Initial results support the efficacy of high-dose aflibercept in RVO, but further data is needed to assess long-term outcomes and safety in real-world settings, emphasizing the importance of ongoing research.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.